Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review

Efficacy results look solid in pair of Phase III trials published in NEJM, but some question whether a double dose adds enough to get approval. Investigators note prevalence of Candida infections in patients on the Novartis drug.